Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer

Sylvia A.A.M. Genet; Esther Visser; Ben E.E.M. van den Borne; Maggy Youssef-El Soud; Huub N.A. Belderbos; Gerben Stege; Marleen E.A. de Saegher; Federica Eduati; Maarten A.C. Broeren; Joost van Dongen; Luc Brunsveld; Daan van de Kerkhof; Volkher Scharnhorst

doi:10.18632/oncotarget.27664

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer

Sylvia A.A.M. Genet, Esther Visser, Ben E.E.M. van den Borne, Maggy Youssef-El Soud, Huub N.A. Belderbos, Gerben Stege, Marleen E.A. de Saegher, Federica Eduati, Maarten A.C. Broeren, Joost van Dongen, Luc Brunsveld, Daan van de Kerkhof _ and Volkher Scharnhorst

Oncotarget. 2020; 11:2660-2668. https://doi.org/10.18632/oncotarget.27664

Metrics: PDF 1559 views | Full Text 3686 views | ?

Abstract

Sylvia A.A.M. Genet1^,4, Esther Visser1^,4, Ben E.E.M. van den Borne2, Maggy Youssef-El Soud3, Huub N.A. Belderbos5, Gerben Stege6, Marleen E.A. de Saegher7, Federica Eduati1^,4, Maarten A.C. Broeren3^,4, Joost van Dongen1^,4, Luc Brunsveld1^,4, Daan van de Kerkhof2^,4 and Volkher Scharnhorst1^,2^,4

1 Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands

2 Catharina Hospital Eindhoven, Eindhoven, The Netherlands

3 Máxima Medical Center, Eindhoven/Veldhoven, The Netherlands

4 Expert Center Clinical Chemistry Eindhoven, Eindhoven, The Netherlands

5 Amphia Hospital, Breda, The Netherlands

6 Sint Anna Hospital, Geldrop, The Netherlands

7 Sint Jans Gasthuis, Weert, The Netherlands

Correspondence to:

Daan van de Kerkhof,

email:

[email protected]

Keywords: small-cell lung cancer; protein tumor markers; neuron-specific enolase; hemolysis correction equation

Received: March 14, 2020 Accepted: June 15, 2020 Published: July 07, 2020

ABSTRACT

Neuron-specific enolase (NSE) is a well-known biomarker for the diagnosis, prognosis and treatment monitoring of small-cell lung cancer (SCLC). Nevertheless, its clinical applicability is limited since serum NSE levels are influenced by hemolysis, leading to falsely elevated results. Therefore, this study aimed to develop a hemolysis correction equation and evaluate its role in SCLC diagnostics.

Two serum pools were spiked with increasing amounts of hemolysate obtained from multiple individuals. A hemolysis correction equation was obtained by analyzing the relationship between the measured NSE concentration and the degree of hemolysis. The equation was validated using intentionally hemolyzed serum samples, which showed that the correction was accurate for samples with an H-index up to 30 μmol/L. Correction of the measured NSE concentration in patients suspected of lung cancer caused an increase in AUC and a significantly lower cut-off value for SCLC detection when compared to uncorrected results.

Therefore, a hemolysis correction equation should be used to correct falsely elevated NSE concentrations. Results of samples with an H-index above 30 μmol/L should not be reported to clinicians. Application of the equation illustrates the importance of hemolysis correction in SCLC diagnostics and questions the correctness of the currently used diagnostic cut-off value.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27664

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer

Abstract